Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 May 29;42(4):32.
doi: 10.1007/s10585-025-10350-5.

Prospective multicentre study of patients with cutaneous metastases from breast cancer treated with electrochemotherapy

Francesco Russano  1 , Giacomo Corrado  2 , Antonio Bonadies  3 , Emilia Migliano  3 , Raimondo di Giacomo  4 , Emanuela Esposito  4 , Claudio Zamagni  5 , Ada Ala  6 , Luca Campana  7 , Tommaso Fabrizio  8 , Matteo Ghilli  9 , Dante Palli  10 , Mariuccia Renne  11 , Roberta Cabula  12 , Fabio Pelle  13 , Barbara Silvestri  14 , Maria Vittoria Dieci  15   16 , Valentina Guarneri  15   16 , Marco Rastrelli  1   15
Affiliations
Multicenter Study

Prospective multicentre study of patients with cutaneous metastases from breast cancer treated with electrochemotherapy

Francesco Russano et al. Clin Exp Metastasis. .

Abstract

Electrochemotherapy (ECT) is a local treatment combining chemotherapy with electroporation. This prospective multicentre study aimed to evaluate the efficacy of ECT in the treatment of patients with skin metastases from breast cancer and confirm whether "luminal A-like" tumors are more responsive to treatment. One-hundred and ninety-five patients were included in the analysis. 55% achieved complete response, 27% partial response (objective response OR 82%); 12% stable disease and 5% experienced progressive disease. The analysis by tumor phenotype showed a significant better response rate in Luminal A-like (p = 0.0060) and Luminal B-like (p = 0.0271) groups compared to Triple-Negative. Patients were divided into 4 groups based on the number and size of cutaneous metastases. Higher response rate was observed in patients with small (≤ 3 cm), single or multiple, metastases (OR rate 95% and 90%, respectively); larger tumors (> 3 cm) showed an OR rate of 85%. Tumor response was not affected by the presence of distant metastases, whereas patients with large cutaneous lesions and distant metastases showed a OR rate of 58%. One-year local progression-free survival (LPFS) was 86% (C.I. 82-89%). In the multivariate analysis, patient age and response to ECT were significantly associated with longer LPFS. This study confirms the efficacy of ECT in small-volume cutaneous metastases from breast cancer regardless the presence of systemic disease and suggests higher efficacy in patients with luminal A- and luminal B-like tumors. ECT can be utilized not only as a palliative measure but also as an alternative treatment for patients not eligible for standard treatments, or in combination with them. Trial registered on https://clinicaltrials.gov/study/NCT06683404 (date of registration 11/11/2024) retrospectively registered.

Keywords: Breast cancer; Cutaneous metastases; ECT; Electroporation; Subcutaneous metastases.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: The study was first approved by the ethics committee of the Veneto Institute of Oncology (CESC-IOV) (protocol code: 4352, date of approval: 10/03/2017). The respective institutional review boards and ethic committees of the participating institutions then approved the study. The study was conducted in accordance with the 1964 Helsinki Declaration and its later amendments. Consent to participate: All patients provided signed informed consent for the procedure and for the use of their data for scientific purposes. Compliance with ethical standards: Research involving Human Participants, Informed consent. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Local progression free survival (LPSF) curves for subgroups of patients
Fig. 2
Fig. 2
Overall survival curves for subgroups of patients
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. 10.3322/caac.21660 - PubMed
    1. Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V (2022) Major advancements in metastatic breast Cancer treatment: when expanding options means prolonging survival. ESMO Open 7:100409. 10.1016/j.esmoop.2022.100409 - PMC - PubMed
    1. Pavese F, Capoluongo ED, Muratore M, Minucci A, Santonocito C, Fuso P, Concolino P, Di Stasio E, Carbognin L, Tiberi G et al (2022) BRCA mutation status in Triple-Negative breast Cancer patients treated with neoadjuvant chemotherapy: A pivotal role for treatment Decision-Making. Cancers 14:4571. 10.3390/cancers14194571 - PMC - PubMed
    1. Daily K, Douglas E, Romitti PA, Thomas A (2021) Epidemiology of de Novo metastatic breast Cancer. Clin Breast Cancer 21:302–308. 10.1016/j.clbc.2021.01.017 - PubMed
    1. Viani GA, Gouveia AG, Louie AV, Korzeniowski M, Pavoni JF, Hamamura AC, Moraes FY (2021) Stereotactic body radiotherapy to treat breast Cancer oligometastases: A systematic review with Meta-Analysis. Radiother Oncol 164:245–250. 10.1016/j.radonc.2021.09.031 - PubMed

Publication types

Associated data

LinkOut - more resources